enables a 2.5-day turn-around time from sample to the final report. Sequencing is performed on high throughput semiconductor sequencing platform to achieve sufficient depth (500x coverage) and accuracy. The workflow is tumor sample only, with no matched normal sample required; germ-line variants, along with background noise, are removed through filters based on population databases. The assay is research use only, not for diagnostic procedures. Results: A comparison with whole exome sequencing (WES) on 12 FFPE tumors, where WES was performed on tumors and their matched normal using Agilent's exome enrichment kit (150x coverage for tumor; 100x coverage for normal) on illumina platform and our assay ran on tumors only, showed high correlation (r2¼0.83) between TMB estimates by our assay with that from WES. To assess reproducibility, we compared raw somatic mutations/Mb in library replicates for a cohort of 21 FFPE research samples (19 CRC, 2 Melanoma) and observed high correlation (r2¼0.97). Our pipeline identifies mutation signatures consistent with specific mechanisms such as UV and tobacco damage, as well as substitutions from FFPE processing. Conclusions: A simple workflow has been developed on the Ion Torrent sequencing platform with an AmpliSeq panel to estimate TMB from FFPE and fresh frozen tumor research samples. This solution will advance research in immuno-oncology. Legal entity responsible for the study: Thermo Fisher Scientific. Background: Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) is a different type of genomic instability in colon cancer (CRC) in contrast to mono-, and dinucleotide based instability microsatellite instability (MSI). In this study, we performed comprehensive genomic profiling (CGP) of CRC patients with different EMAST and MSI status to understand their genomic structure, which may help match them with relevant therapies. Methods: 99 formalin-fixed, paraffin-embedded (FFPE) CRC tissues consisting of four subtypes based on their EMAST and MSI status, namely (1) EMASTþ and MSI-high (MSI-H), (2) EMASTþ and microsatellite-stable (MSS), (3) EMAST-and MSI-H, and (4) EMATS-and MSS, were subjected to next-generation sequencing (NGS) with a 440-gene panel to identify mutations and copy number variants (CNVs). Tumor mutational burden (TMB) was determined using mutations detected on exonic regions sequenced while CNV index was calculated to infer genome instability. Results: In line with previous studies, the prevalence of TP53 (17.6%; n ¼ 3) and APC (23.5%; n ¼ 4) mutations was much lower whereas BRAF V600 mutation (41.2%; n ¼ 7) was much higher in the subtype (1) CRCs which had both MSI-H and EMAST signatures. Interestingly, these dual positive tumors had a significant higher TMB and lower CNV index than other subtypes (TMB: (1) vs (2), (3) and (4); 54 vs 19, 25; and 16; p < 0.0001, CNV index: (1) vs (2), (3), and (4); 3.9 vs 13.7, 9.9, and 17.8; p < 0.0114, 0.006, and 0.0003), suggesting there are more likely to benefit from immune checkpoint inhibitors. Notably, ATM and ARID1A genes mutated in a mutually exclusive way in up to 13/17 (76.5%) of tumors with MSI-H and EMAST signatures, which may predict treatment benefit from the PARP inhibitors. Conclusions: MSI-H and EMASTþ CRCs show distinctive genomic features that give them the potential opportunity for checkpoint inhibitors in combination with PARP inhibitors. Legal entity responsible for the study: ACT Genomics. Background: The FGF signaling network plays a key role in tumorigenesis and is recognized as a potential therapeutic target. FGF23 is predominately expressed in bone osteocytes and can act as an autocrine, paracrine and/or endocrine growth factor in
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